|
TOTAL COHORT N(%) or Median(IQR) N=2457 |
CAUCASIAN N(%) or Median(IQR) N=1040 |
AFRICAN-AMERICAN N(%) or Median (IQR) N=1052 |
HISPANIC N(%) or Median(IQR) N=231 |
OTHER N(%) or Median(IQR) N=134 |
P-VALUE | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age(years) | 34 (11.0) | 36 (10.0) | 34 (11.0) | 32 (12.0) | 33 (11.0) | <.0001 |
| Gender(%Female) | 212 (8.6%) | 63 (6.1%) | 114 (10.8%) | 12 (5.2%) | 23 (17.2%) | <.0001 |
| Marital Status(%Married) | 762 (31.0%) | 301 (28.9%) | 352 (33.5%) | 70 (30.3%) | 39 (29.1%) | 0.1504 |
| Rank Status | <.0001 | |||||
| Officer/Warrant | 238 (9.7%) | 170 (16.3%) | 50 (4.8%) | 9 (3.9%) | 9 (6.7%) | |
| Enlisted | 1962 (79.9%) | 759 (73.0%) | 914 (86.9%) | 196 (84.8%) | 93 (69.4%) | |
| Missing | 257 (10.5%) | 111 (10.7%) | 88 (8.4%) | 26 (11.3%) | 32 (23.9%) | |
| Duty Status at Diagnosis | 0.0009 | |||||
| Active | 2068 (84.2%) | 871 (83.8%) | 905 (86.0%) | 193 (83.5%) | 99 (73.9%) | |
| Retired | 117 (4.8%) | 51 (4.9%) | 48 (4.6%) | 12 (5.2%) | 6 (4.5%) | |
| Dependent | 134 (5.5%) | 49 (4.7%) | 52 (4.9%) | 14 (6.1%) | 19 (14.2%) | |
| Other | 138 (5.6%) | 69 (6.6%) | 47 (4.5%) | 12 (5.2%) | 10 (7.5%) | |
| Site | <.0001 | |||||
| NMCP | 177 (7.2%) | 67 (6.4%) | 92 (8.8%) | 14 (6.1%) | 4 (3.0%) | |
| NMCSD | 356 (14.5%) | 169 (16.3%) | 89 (8.5%) | 61 (26.4%) | 37 (27.6%) | |
| SAMMC | 736 (30.0%) | 350 (33.7%) | 263 (25.0%) | 84 (36.4%) | 39 (29.1%) | |
| TAMC | 64 (2.6%) | 25 (2.4%) | 13 (1.2%) | 6 (2.6%) | 20 (14.9%) | |
| WRNMMC | 1124 (45.8%) | 429 (41.3%) | 595 (56.6%) | 66 (28.6%) | 34 (25.4%) | |
| HIV Related (to/at HAART initiation) | ||||||
| HIV Diagnosis (months) | 34.9 (84.8) | 38.7 (85.4) | 35.7 (86.5) | 16.0 (54.8) | 14.5 (64.3) | <.0001 |
| Viral load at HAART Initiation (log10copies/ml) | 0.0240 | |||||
| <400 | 222 (9.0%) | 89 (8.6%) | 101 (9.6%) | 19 (8.2%) | 13 (9.7%) | |
| 400-<1000 | 236 (9.6%) | 111 (10.7%) | 104 (9.9%) | 12 (5.2%) | 9 (6.7%) | |
| 1000-<10000 | 474 (19.3%) | 215 (20.7%) | 184 (17.5%) | 43 (18.6%) | 32 (23.9%) | |
| >=10000 | 1428 (58.1%) | 583 (56.1%) | 629 (59.8%) | 147 (63.6%) | 69 (51.5%) | |
| Missing | 97 (4.0%) | 42 (4.0%) | 34 (3.2%) | 10 (4.3%) | 11 (8.2%) | |
| CD4∗ Cell Count at HAART initiation(cells/ml) | . | 0.1180 | ||||
| <200 | 509 (20.7%) | 213 (20.5%) | 224 (21.3%) | 46 (19.9%) | 26 (19.4%) | |
| 200-<350 | 732 (29.8%) | 299 (28.8%) | 333 (31.7%) | 64 (27.7%) | 36 (26.9%) | |
| >=350 | 1079 (43.9%) | 483 (46.4%) | 426 (40.5%) | 109 (47.2%) | 61 (45.5%) | |
| Missing | 137 (5.6%) | 45 (4.3%) | 69 (6.5%) | 12 95.2%) | 11 (8.2%) | |
| Period of HAART Initiation | ||||||
| 1996-2001 | 1608 (65.4%) | 709 (68.2%) | 705 (67.0%) | 126 (54.5%) | 68 (50.7%) | <.0001 |
| 2002-2007 | 477 (19.4%) | 208 (20.0%) | 194 (18.4%) | 45 (19.5%) | 30 (22.4%) | 0.6542 |
| 2008-2012 | 372 (15.1%) | 123 (11.8%) | 153 (14.5%) | 60 (26.0%) | 36 (26.9%) | <.0001 |
| Initial HAART Regimen | ||||||
| NNRTI | 837 (34.1%) | 327 (31.4%) | 371 (35.3%) | 85 (36.8%) | 54 (40.3%) | 0.8847 |
| Boosted PI | 169 (6.9%) | 66 (6.3%) | 63 (6.0%) | 21 (9.1%) | 19 (14.2%) | 0.0736 |
| Unboosted PI | 1247 (50.8%) | 552 (53.1%) | 540 (51.3%) | 108 (46.8%) | 47 (35.1%) | 0.0021 |
| Integrase Inhibitor | 33 (1.3%) | 16 (1.5%) | 12 (1.1%) | 11 (4.8%) | 4 (3.0%) | 0.0007 |
| 3NRTI | 67 (2.7%) | 22 (2.1%) | 30 (2.9%) | 3 (1.3%) | 2 (1.5%) | 0.1599 |
| Other | 104 (4.2%) | 57 (5.5%) | 36 (3.4%) | 3 (1.3%) | 8 (6.0%) | 0.0069 |
|
Comorbidities |
||||||
| Chronic Viral Hepatitis | 274 (11.2%) | 104 (10.0%) | 134 (12.7%) | 24 (10.4%) | 12 (9.0%) | 0.1831 |
| Malignancy other than Basal Cell Carcinoma | 273 (11.1%) | 171 (16.4%) | 81 (7.7%) | 12 (5.2%) | 9 (6.7%) | <.0001 |
| Diabetes Mellitus | 201 (8.2%) | 82 (7.9%) | 92 (8.7%) | 19 (8.2%) | 8 (6.0%) | 0.6962 |
| Coronary Artery Disease | 71 (2.9%) | 46 (4.4%) | 16 (1.5%) | 7 (3.0%) | 2 (1.5%) | 0.0008 |
| Anxiety Disorder | 215 (8.8%) | 128 (12.3%) | 50 (4.8%) | 24 (10.4%) | 13 (9.7%) | <.0001 |
| Major Depression | 594 (24.2%) | 274 (26.3%) | 225 (21.4%) | 56 (24.2%) | 39 (29.1%) | 0.0305 |
| Substance Abuse | 283 (11.5%) | 135 (13.0%) | 104 (9.9%) | 31 (13.4%) | 13 (9.7%) | 0.1029 |
| Serum Levels at HAART Initiation | ||||||
| ALT(U/L) | 32 (25) | 32 (25) | 32 (23) | 35 (28) | 32 (23) | 0.3194 |
| Creatinine (mg/dL) | 1.0 (0.2) | 1.0 (0.2) | 1.0 (0.3) | 0.9 (0.3) | 0.9 (0.3) | <.0001 |
| Hemoglobin(g/dL) | 14.3 (1.9) | 14.6 (1.8) | 13.9 (1.8) | 14.7 (1.7) | 14.8 (1.8) | <.0001 |